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Background: three randomized open-label clinical trials [Simplified Antibi-
otic therapy trial (SAtt) Bangladesh, SAtt pakistan and African neonatal 
Sepsis trial (AFRIneSt)] were developed to test the equivalence of simpli-
fied antibiotic regimens compared with the standard regimen of 7 days of par-
enteral antibiotics. these trials were originally conceived and designed sepa-
rately; subsequently, significant efforts were made to develop and implement 
a common protocol and approach. previous articles in this supplement briefly 
describe the specific quality control methods used in the individual trials; this 
article presents additional information about the systematic approaches used 
to minimize threats to validity and ensure quality across the trials.
Methods: A critical component of quality control for AFRIneSt and SAtt 
was striving to eliminate variation in clinical assessments and decisions regard-
ing eligibility, enrollment and treatment outcomes. ensuring appropriate and 
consistent clinical judgment was accomplished through standardized approaches 
applied across the trials, including training, assessment of clinical skills and 
refresher training. Standardized monitoring procedures were also applied across 
the trials, including routine (day-to-day) internal monitoring of performance 
and adherence to protocols, systematic external monitoring by funding agencies 
and external monitoring by experienced, independent trial monitors. A group of 
independent experts (technical Steering Committee/technical Advisory Group) 
provided regular monitoring and technical oversight for the trials.
Conclusions: Harmonization of AFRIneSt and SAtt have helped to 
ensure consistency and quality of implementation, both internally and 
across the trials as a whole, thereby minimizing potential threats to the 
validity of the trials’ results.
Key Words: community-based research, quality assurance, trial monitoring
(Pediatr Infect Dis J 2013;32:S39–S45)
T
o address the priority research needed to identify effective alterna-
tive, simplified antibiotic regimens for community-based manage-
ment of newborn sepsis, 3 clinical trials were conceived and imple-
mented, as previously described.1 each of these trials was designed 
as a randomized open-label trial to test the equivalence of simplified 
antibiotic regimens compared with the more complex standard regi-
men of 7 days of parenteral antibiotics. trials known as the Simplified 
Antibiotic therapy trials (SAtts) were designed separately; through 
a 2008 consultation convened by the Bill and melinda Gates Founda-
tion (BmGF) and subsequent meetings, the separate study protocols 
were harmonized as a single, common protocol to be implemented in 
each country. Implementation of SAtt started first in Bangladesh in 
July 2009 followed by pakistan in January 2010. the African neo-
natal Sepsis trial (AFRIneSt) was subsequently initiated in 2010 
and was designed to use the same protocol (with additional arms) and 
outcomes as SAtt in sub-Saharan Africa [the Democratic Republic 
of the Congo (DRC), Kenya and nigeria].
the main objective of SAtt and AFRIneSt was to evaluate 
simplified alternative antibiotic regimens of antibiotics that could 
subsequently be recommended for community-based management 
of serious infections in newborns and young infants. eligible par-
ticipants include newborns and young infants (0–59 days old) with 
suspected serious infection, whose families do not accept or comply 
with referral for hospital-based treatment. the trial methods have 
been described in detail elsewhere.2–5 Although these research trials 
were originally conceived and funded separately, subsequent efforts 
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were undertaken to harmonize the trials to ensure consistency and 
quality, both internally and across the trials as a whole.1 the Bangla-
desh SAtt, developed by the Johns Hopkins university and Dhaka 
Shishu Hospital, was originally funded by united States Agency 
for International Development (uSAID). the pakistan SAtt was 
developed by Aga Khan university (Karachi) and was funded by 
the Saving newborn lives initiative (Snl) of Save the Children 
with support from BmGF, with additional funding provided by 
World Health Organization (WHO) and uSAID. AFRIneSt was 
originally conceived and developed by WHO in consultation with 
Snl and uSAID with funding from BmGF. through a system-
atic proposal development process, principal investigators (pIs) 
of AFRIneSt were selected from nigeria (university of Ibadan, 
Obafemi Awolowo university and Ahmadu Bello university), DRC 
(Kinshasa School of public Health) and Kenya (moi university).
previous articles in this supplement1–5 have included infor-
mation on the unique internal quality control processes that were 
used within each separate trial, as well as the development of a 
common protocol (including standardized definitions and terminol-
ogies) for the trials as a whole. this article focuses on the quality 
assurance: it presents the methods used for quality control across 
SAtt and AFRIneSt and additional information regarding efforts 
to harmonize the trial-specific internal monitoring procedures.
QUALITY CONTROL METHODS IN  
AFRINEST AND SATT
Potential Threats to Validity
During the planning and design stages of AFRIneSt and 
SAtt, study teams identified inherent design-related issues that 
had the potential to threaten the quality of the studies and valid-
ity of results. Significant efforts were made to develop systematic 
approaches to minimize these challenges and ensure quality of 
implementation. A primary concern was that the enrollment and 
treatment outcome criteria rely on clinical judgment, as opposed to 
objective measures, such as laboratory confirmation of severe infec-
tion or death as the primary outcome. Reliance on subjective deter-
mination of clinical signs of severe infection presents the potential 
for misidentification of clinical signs of severe infection and of 
enrolling patients with different types of illnesses and infections. 
Were this threat not effectively mitigated by quality control efforts, 
otherwise strong evidence of antibiotic regimen equivalence might 
be considered inconclusive. the determination of treatment fail-
ure, with the exception of death, also relies on clinical assessment; 
this poses a similar threat to conclusive evidence of equivalence. 
In addition, the trials are open-label, meaning that study personnel 
and participants are not masked to treatment assignment and thus 
know which therapeutic regimen an infant is receiving. the nature 
of these trials did not allow for masking the treatment regimen. pla-
cebo injections would not be ethical, and sham injections would be 
potentially unethical and logistically problematic. the pIs, donors 
(BmGF and uSAID) and trial technical steering committee (tSC) 
and technical advisory group (tAG) therefore undertook rigor-
ous quality control methods to mitigate these and other potential 
threats, to internal validity within and across these trials.
Ensuring Quality
Development of SATT Quality Control Measures
Because the 2 Asia SAtts were separately funded and 
administered, special efforts were undertaken to coordinate the 
studies’ implementation, technical oversight, data management and 
quality control. Snl was specifically funded by BmGF to organ-
ize a mechanism of technical oversight and monitoring for the 2 
SAtts in Asia, using independent technical experts with experience 
in design and implementation of clinical trials in developing coun-
tries, pediatrics, infectious diseases, ethics and biostatistics. this 
mechanism was mutually agreed to and planned by the pIs, fund-
ing agencies (Snl and uSAID), WHO and BmGF; thus, a tSC 
was formed, consisting of independent experts, pIs, WHO, BmGF, 
uSAID and Snl. A major initial concern was the need for stand-
ardized trial monitoring across the 2 SAtts to ensure uniform and 
high-quality implementation and internal monitoring procedures as 
much as possible. the tSC first considered whether an independ-
ent contract research organization (CRO) would be able to provide 
the necessary cross-site monitoring functions. the tSC held discus-
sions with potential CROs and also specifically identified, together 
with the pIs, the particular issues that needed to be addressed to 
robustly mitigate the major threats to validity. the conclusion from 
these investigations and discussions was that CROs, in general, were 
not the most appropriate mechanism for monitoring in these trials. 
this was based on the limited capacity of CROs to specifically mon-
itor the clinical standardization and quality control required for trials 
that rely on clinicians’ skills and judgment to determine enrollment 
eligibility and treatment outcomes. the SAtt tSC identified the 
following as key to quality control within and across sites:
1. Development and use of standardized protocols for clinical 
assessments for enrollment eligibility and treatment outcomes.
2.  Development and use of standardized internal study team moni-
toring procedures to routinely assess and refresh clinical skills 
and judgments of staff.
3. Frequent and standardized monitoring visits by tSC members, 
using WHO site visit monitoring guidelines and checklist.
the SAtt tSC used an external clinical monitoring expert, 
who was a trained pediatrician, to independently review the sites 
and make specific recommendations to standardize and harmonize 
all aspects of study implementation, clinical skills and judgments, 
and quality control procedures. these visits resulted in modifica-
tion of standard operating procedures (SOps) in both SAtts, par-
ticularly standardization across sites of clinical assessment and 
internal quality control methods.
Development of AFRINEST Quality Control 
Measures
AFRIneSt is a single trial funded entirely by BmGF, with 
5 sites and pIs in 3 sub-Saharan African countries, led and coordi-
nated by a technical team at WHO. From the outset, AFRIneSt 
used the common protocol that was developed initially for SAtt. 
modifications in implementation were necessary due to contextual 
factors, including differences in health delivery platforms between 
SAtt Asia sites and those in the AFRIneSt locations. As noted 
in the methods of previous articles,4,5 additional antibiotic regi-
mens were tested in AFRIneSt, including a simplified regimen for 
young infants with fast breathing only. the quality control measures 
instituted for AFRIneSt were based on the development of SOps, 
uniformly applied across all sites, including standardized training, 
WHO monitoring visits, assessment of clinical skills, refresher 
training and use of an external monitor for independent review.
SATT and AFRINEST Common Approaches to 
Quality Control
A critical component of quality control for AFRIneSt and 
SAtt was striving to eliminate variation in clinical assessments and 
decisions regarding eligibility, enrollment and treatment outcomes. 
While each of the trials adopted procedures specific for the setting, 
there was a uniform effort across the trials to assure that each “treat-
ment failure” assignment was correct. In Bangladesh and pakistan, The Pediatric Infectious Disease Journal  •  Volume 32, Number 9, Supplement, September 2013  AFRINEST and SATT
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the outcome assessor may know the infant’s treatment assignment. 
Infants who are identified as failing treatment (during routine fol-
low-up) receive a second assessment by a different study physician; 
this second assessor is blinded to the infant’s treatment assignment 
and history. If the 2 assessments disagree, the decision is referred 
to a supervising senior physician who makes the final determina-
tion. the AFRIneSt sites use a separate “independent outcome 
assessor:” a nurse who is responsible for performing the outcome 
assessment and who is blinded to the infant’s treatment assignment. 
ensuring appropriate and consistent clinical judgment was accom-
plished through a combination of approaches, applied across the tri-
als, including training standardization, routine (day-to-day) internal 
monitoring, systematic external monitoring by funding agencies and 
external monitoring by experienced, independent trial monitors.
Training and Standardization
AFRIneSt and SAtt use different cadres of health work-
ers [including physicians, nurses and community health workers 
(CHWs)] and have implemented standard training protocols to 
ensure common understanding and clinical judgment among and 
across all cadres.
In AFRIneSt, an initial training-of-trainers was conducted 
to train the pIs; the pIs then led trainings at each study site for local 
study staff. WHO technical monitors visited each site as soon as 
the training of health workers was underway to conduct a stand-
ardization exercise (Appendix 1) to check clinical assessment skills 
of the study staff. those staff who did not meet preset criteria in 
the standardization exercise were immediately retrained; if they did 
not perform well after retraining, they were withdrawn from the 
study. Staff who met the performance criteria were assigned to roles 
within the study based on the knowledge and skills demonstrated 
during the standardization exercise (eg, the highest performing 
nurses were assigned to be independent outcome assessors). Regu-
lar refresher trainings are conducted by the pIs every 3–6 months; 
additional standardization exercises are held at 3- or 6-month inter-
vals (depending on the type of study staff). Results of the stand-
ardization exercises are input into a spreadsheet (microsoft excel) 
and scores outside the standard range are marked; those staff who 
do not perform well (eg, not conducting the required number of 
follow-up visits or performing poorly on clinical assessments) are 
retrained on specific areas in which their performance is low and 
reassessed before they are allowed to continue.
In SAtt, intensive training was also conducted at the start of 
the trials. Refresher training sessions and standardization exercises 
are held regularly to ensure consistency in eligibility and treatment 
outcome evaluation. In Bangladesh, refresher trainings and stand-
ardization exercises are conducted quarterly; weekly meetings of 
the study staff also provide opportunities for “continuing educa-
tion” through review of randomly selected cases of severe infection 
and discussion of any discrepancies in the assessors’ identification 
of clinical signs (Appendix 2). In pakistan, refresher trainings and 
standardization exercises are conducted on a monthly basis; the pri-
mary goal of these activities was to reinforce knowledge and skills 
related to clinical assessment (Appendix 3). Video recordings of 
selected infants with and without clinical signs of severe infection 
are used to assess and refresh skills.
Internal Monitoring
SOps were developed for AFRIneSt and SAtt to guide the 
operational and clinical activities of the trials; this included SOps 
for internal monitoring. the main objective of internal monitoring 
was to verify that the study protocol and SOps are being followed 
correctly. As with other aspects of the trials, internal monitoring 
approaches were harmonized across all sites to ensure similar high 
levels of quality and safety. In all cases, feedback from the routine 
internal monitoring is presented and discussed with the appropriate 
members of the study team on an ongoing, real-time basis.
In AFRIneSt, pIs conduct routine monitoring visits to 
study sites and use a standard checklist developed by WHO. these 
visits include checking study equipment and supplies (eg, weigh-
ing scales), as well as conducting supervision activities for study 
staff. Scheduled and unscheduled visits are performed by pIs and 
field supervisors; a standardized checklist is used to monitor the 
skills of CHWs, treatment nurses and outcome assessors regard-
ing identification of danger signs, classification, eligibility crite-
ria, randomization and consent procedures, treatment and injection 
technique. At a minimum, 5% of a nurse’s/CHW’s visits must be 
directly observed; outcome assessment nurses must be observed 
during at least 20% of their visits. If errors or gaps in skills are 
observed during a supervisory visit, immediate feedback is given 
to the study team member.
In the SAtt Bangladesh trial, a SOp was developed to guide 
the operational and clinical activities of the trial; this included 
SOps for internal monitoring. the main objective of internal moni-
toring was to verify that the study protocol and SOp were being fol-
lowed correctly. As with other aspects of the trial, internal monitor-
ing approaches were harmonized across all sites to ensure similar 
levels of quality and safety. In all cases, feedback from the routine 
internal monitoring was presented and discussed with the appropri-
ate members of the study team on an ongoing, real-time basis.
Site visits were conducted by study coordinators and by 
investigators (and/or consultant experts) in the SAtt Bangladesh 
trial. the study coordinator is allocated 2 days every month for 
each site for this purpose. One day is randomly selected for each 
site for the monitoring visit, and the visit is completed on the next 
day. the coordinator uses a standard monitoring checklist (devel-
oped by WHO) to guide the visit, which includes evaluating study 
management, reviewing subject records and observing key study 
procedures. Findings are shared with the local study team and with 
investigators. A trip report is submitted after each monitoring visit. 
One random day is selected per month for each site to be visited 
by study investigators/consultants for a monitoring and supervision 
visit. the first 5 cases on the selected day are selected for a study 
physician to assess (the clinical component only) and the inves-
tigators/consultants to observe. Only disagreements are recorded, 
and the reason for disagreements are immediately addressed and 
discussed. these random visits are planned to ensure that all study 
physicians are subjected to a validation exercise once in a 3-month 
period. For clinical signs about which the investigators disagreed 
with study physicians’ assessment, a database is kept; these signs 
are also emphasized during refresher training.
In SAtt pakistan, routine internal monitoring is conducted 
on a daily basis by 2 dedicated clinician supervisors who observe 
the screening and enrollment process, randomization and the deliv-
ery of therapy. they also observe approximately 20% of interviews 
conducted by study physicians, perform spot checks and formally 
reinterview 10% of participants interviewed by study physicians. 
Finally, supervisors check case files for errors, inconsistencies and 
missing values. Additional monitoring visits are conducted by an 
“internal auditor:” a physician and monitoring expert who is not 
associated with the trials. the auditor performs a random visit once 
a month to observe and review clinical practices in the study; a 
standardized checklist is used and feedback is provided directly to 
the pI, research supervisor and field team.
External Monitoring
Both AFRIneSt and SAtt receive structured external 
monitoring visits from WHO monitors and other members of their Wall et al  The Pediatric Infectious Disease Journal  •  Volume 32, Number 9, Supplement, September 2013
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respective tAG (AFRIneSt) or technical steering committee 
(SAtt). WHO technical staff, following a standard WHO site mon-
itoring guideline/checklist (Appendix 4), visit each AFRIneSt site 
at least once every 6 months. A detailed structured review of study 
implementation is conducted at each visit, including recruitment 
rate, clinical practices (eg, identification of danger signs and critical 
signs, detection of treatment failure), data management and overall 
study procedures. All study documentation is checked, and a pro-
portion of completed case report forms (including all reports of 
treatment failure and adverse events) is reviewed. the recommen-
dations arising from the site visit are discussed with the pIs at the 
sites and followed up for actions taken and dates. At least once per 
year, the SAtt Bangladesh and pakistan sites receive structured 
external monitoring visits from a WHO technical expert, either 
alone or accompanied by Snl/SC technical staff and independent 
tSC member(s). Additional ad hoc monitoring visits by external 
tSC members are conducted for SAtt Bangladesh, mostly in con-
junction with tSC/Data Safety monitoring Board (DSmB) meet-
ings, which are frequently held in Dhaka. Additional ad hoc visits 
are intended for SAtt pakistan but are subject to security restric-
tions for non-pakistanis. the format for SAtt external monitor-
ing visits is similar to AFRIneSt: recommendations and written 
feedback are provided, and the pI subsequently updates the tSC on 
actions taken in response to each recommendation. the same WHO 
site monitoring checklist is used to structure the SAtt monitoring 
process and to standardize across all sites.
In addition, all sites have been visited by an independent exter-
nal trial monitor who examined study implementation and adherence 
to protocols and Good Clinical practices standards. For SAtt sites 
(Bangladesh and pakistan), the external monitor conducted an inde-
pendent assessment of clinical and quality control procedures and 
made recommendations on how to standardize or harmonize all such 
processes. pIs followed these recommendations to implement uniform 
internal monitoring and quality control procedures. In AFRIneSt, an 
independent external monitor visited each site, provided an assess-
ment using the same protocol as WHO monitors (Appendix 4), made 
recommendations for each separate sites that were implemented by 
pIs and then checked for by WHO during routine monitoring.
Technical Advisory Groups
two external advisory groups were set up for the trials: 
AFRIneSt formed a tAG and SAtt formed a tSC to oversee the 
2 trials in Bangladesh and pakistan. these bodies are responsible for 
providing broad technical oversight for the trials. In the case of SAtt, 
the tSC adds unique value by facilitating coordination and harmo-
nization for the 2 separate studies. the SAtt tSC has played an 
active role to provide coordinated oversight for the 2 separate trials, 
as explained above. this includes routine external monitoring visits, 
including visiting homes and clinics to observe enrollment and man-
agement of patients; the tSC then makes recommendations based 
on its observations and follow-up to ensure recommendations appro-
priately reviewed and implemented by each trial. the AFRIneSt 
tAG is not needed to provide coordination of technical oversight, 
as this was done by WHO as the coordinating agency for the trial. 
the AFRIneSt tAG has been convened for annual review meetings 
but has not engaged in direct field-level monitoring in the same way 
that it is done by the SAtt tSC. membership of the tAG and tSC 
includes experts from a variety of areas, including clinical pediatrics, 
neonatology and infectious diseases; global clinical trials (includ-
ing ethics); epidemiology and biostatistics; and global health policy. 
there was an intentional overlap in the tAG and tSC membership; a 
number of individuals were selected to serve on both groups to facili-
tate greater harmonization between the trials. the SAt tSC holds 
quarterly and as-needed conference calls to review quarterly data 
and discuss technical issues, as well as annual in-person meetings. 
the AFRIneSt tAG holds teleconferences on an as-needed basis 
throughout the year, as well as annual in-person meetings.
Data Safety Monitoring Boards
two DSmBs were formed, 1 for AFRIneSt and 1 for SAtt 
(Bangladesh and pakistan combined), each with 5 members: 1 epi-
demiologist, 1 statistician and 3 clinicians/researchers. members of 
the DSmB are not involved in the design or conduct of the trials. 
these groups are tasked with monitoring and assessing the safety 
of the trials (based on reports); responsibilities include ensuring 
patient safety within each site, setting up “stop rules” based on 
ethical and public health considerations, reviewing interim analysis 
data and recommending appropriate actions to be taken by the pIs. 
the DSmBs meet annually with the pIs and tSC/tAG and commu-
nicate among members via e-mail and teleconferences as needed to 
review data and make recommendations to pIs.
Data Management
there are 3 levels of data management and quality assur-
ance in AFRIneSt and SAtt: local data management and qual-
ity control practices at study sites and within the individual trials; 
technical oversight, review and quality control for data manage-
ment from the tSC/tAG; and external monitoring visits and high-
level data management, review and quality checks performed by 
the data management team at the london School of Hygiene and 
tropical medicine (lSHtm). methods for site-level and individual 
trial-level data management have been described elsewhere.2–5 the 
team at lSHtm performs a standard set of range and consistency 
checks for all data sent from the individual sites. Data are archived 
at lSHtm, and reports are generated as required by IRBs, the 
AFRIneSt Coordinator (WHO) and tAG, and the SAtt tSC.
Routine external monitoring visits include review of study 
data and data management procedures. Specifically, database and 
CRFs are reviewed for all death and treatment failure cases, and a 
random sample is taken of approximately 10–20% of eligible and 
enrolled cases. Finally, lSHtm provides data management and 
analysis support for both AFRIneSt and SAtt. AFRIneSt sub-
mits data to lSHtm on a monthly basis; these data are shared with 
WHO monthly and with the tAG annually. the SAtt trial sites 
submit their data to lSHtm on a quarterly basis, and the data are 
shared with the tSC quarterly for review. lSHtm also provides 
routine data summaries of deaths, treatment failures and severe 
adverse events for regular review by each DSmB.
Strategic Planning Committee
the Strategic planning Committee is composed of 
AFRIneSt and SAtt funding agency representatives and chairs 
of the tSC and tAG. Its primary purpose was to review the tri-
als’ progress and to provide strategic direction for planned study 
analyses to answer questions of global policy relevance. the Stra-
tegic planning Committee provides general strategic direction to 
maximize policy impact, based on efforts to ensure sound evidence, 
relevant evidence from both trials.
CONCLUSIONS
to ensure quality of implementation and to minimize poten-
tial threats to validity, AFRIneSt and SAtt adopted a variety of 
purposeful quality control approaches; these were similar or the 
same across the trials. Key quality control processes have included 
standardization of training efforts and assessment of clinical skills, 
routine internal monitoring of study protocol adherence, and exter-
nal monitoring and oversight of study implementation by funders 
and independent experts.The Pediatric Infectious Disease Journal  •  Volume 32, Number 9, Supplement, September 2013  AFRINEST and SATT
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APPENDIX 1. AFRINEST CLINICAL ASSESSMENT 
STANDARDIZATION PROCEDURE
1. Identify 5–10 eligible young infants in a community. Ask 
up to 5 CHWs (one by one) to assess 1 young infant being 
observed by the trained facilitator, both using Form 2 to 
record all findings. this process is repeated with each CHW 
by the facilitator.
2. Identify 5–10 eligible young infants in a health facility. Ask up 
to 5 enrollment or treatment or health center nurses/supervi-
sors/coordinators (one by one) to assess 1 young infant being 
observed by the trained facilitator, both using Form 3 to record 
all findings. this process is repeated with each person by the 
facilitator.
3. then the data are entered in a simple excel sheet. For the pur-
pose of this exercise if the facilitator and the health worker dif-
fer in their assessment, it is categorized as an “error.” For res-
piratory rate ±2 breaths per minute; for weight ±0.1 kg and for 
temperature ±0.1°C is acceptable. If the difference between the 
facilitator and the HW is more than the preceding differences, 
then that is considered an error. At the bottom of the sheet, we 
total the errors over the observations (see example).
4. If the time is short and the young infant cannot be exposed for 
long due to sickness, the history can be taken by 1 CHW or 
nurse with other CHWs or nurses/supervisors recording the 
same information, but the examination has to be done separately 
at the same time with the trained supervisors.
5. Such standardization exercises were done with all health work-
ers. errors were improved by further practice and refresher train-
ing if necessary. A 5% error may be acceptable before the health 
worker starts enrolling patients. Workers who did not improve 
were replaced.
APPENDIX 2. SATT BANGLADESH CLINICAL 
ASSESSMENT STANDARDIZATION PROCEDURE
Eligibility Assessment Standardization at Hospital
In a calendar month, 2 days were randomly selected for eli-
gibility assessment standardization in each of the 5 study sites (an 
estimated 6% of the total screening). two study physicians inde-
pendently assessed all young infants for eligibility on the randomly 
selected days. the assessment of the first physician was entered in 
regular database. Second independent assessment was recorded on 
a separate data form. Analysis by each sign and overall determina-
tion of eligibility was conducted on weekly basis to find discrepan-
cies and was discussed in weekly meeting as part of continuing 
training. Refresher training for standardization of assessments was 
conducted quarterly. In refresher training, special attention was 
given to the signs for which there were more discrepancies between 
the 2 independent physicians.
Follow-up Standardization at Home
Independent assessment of 5% of all home follow-ups was 
conducted by a second physician. An excel program was used 
to randomly select 5% of all follow-ups. Random numbers for 
follow-up IDs were generated every morning. the study coor-
dinator assigned 2 study physicians to follow-up the randomly 
selected cases and organized the field follow-up schedule to 
ensure about an hour gap between the 2 assessments. Data of 
first physician’s follow-up were entered into regular database, 
and second physician’s assessment was entered into separate 
database. Data analysis was done weekly, and discrepancies were 
discussed in the weekly meeting. the discrepancies were taken 
into account during quarterly refresher training to standardize 
the assessments.
Ascertainment of Treatment Failure 
Standardization
All infants found to met clinical treatment failure criteria by 
study physicians on routine follow-up was designated as “provi-
sional” treatment failures and were transported to hospital, accom-
panied by study personnel. At the hospital, the infant underwent 
a repeat examination by a second study physician. to the extent 
possible, the second physician assessor was blinded to the treat-
ment allocation and prior history of the infant. If the second assess-
ment supported the ascertainment of treatment failure, the case was 
considered a “confirmed” treatment failure. If the second medical 
assessment did not lead to the ascertainment of treatment failure 
(ie, disagreed with first assessment), the case was referred to a 
supervising senior physician. the decision of the senior physician 
was considered as final.
APPENDIX 3. SATT PAKISTAN CLINICAL 
ASSESSMENT STANDARDIZATION PROCEDURE
1.  Initial training
1.1   Initial training consisted of 2 days classroom lectures, 2 days 
in tertiary care hospital and 2 days at field sites (total 6 days 
training).
1.2   In classroom setting trial protocol, standard operation pro-
cedures, case report from, drug and doses, outcome defini-
tion and ascertainment discussed and 20 videos of clinical 
signs are shown.
1.3   In tertiary care hospital, each physician examines 15 infants 
for presence or absence of clinical signs, being observed by 
a trained facilitator (pediatric consultant).
1.4   In field sites, physicians examine 5 infants under supervi-
sion of research supervisor, including anthropometry meas-
urements and record their findings, which are compared 
with supervisor’s findings.
2.  monthly standardization exercises
2.1   ten videos (including both sick and normal young infants) 
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2.2    Study physicians recording their findings on an answer 
sheet. Answer sheet checked by senior clinician and feed-
back provided.
2.3   physicians who get 4 or more incorrect identifications on 
3 consecutive tests are provided with full refresher training 
(see below).
3.  Biannual refresher training and standardization:
3.1   One week refresher training is conducted twice a year.
3.2   trial protocol and standard operation procedures reviewed.
3.3   20 videos of clinical signs in young infants are shown for 
identification of signs.
3.4   Individual assessment test includes clinical signs identifica-
tion as well as protocol.
APPENDIX 4. WHO CHECKLIST FOR SITE 
MONITORING VISITS
Prerequisite
  • pre-agreed agenda and timing of the visit with the investigators.
Actual visit
  • meeting with pI and other study staff during the visit and dis-
cuss aspects of the study progress.
the following are carried out by review/observation/checking:
1.  StuDY mAnAGement ReVIeW
  • Documentation:
  • updated protocol with all the approved amendments
  • procedures manual/standard operating procedures
  • Consent forms
  • Communications with the local IRB
  • IRB approval
  • Storage of documents:
  • Designated data cabinets
  • Adequate storage of case report forms (CRF)
  • progress of the study/enrollment:
  • expected recruitments
  • Actual recruitments
  • Other relevant aspects
(include justification if discrepancy >10%)
  • Screening of patients and enrollment records:
  • Completeness
  • Adequacy of storage
  • maintenance of screening calendars/forms:
  • Completeness
  • Adequacy of storage
  • maintenance of follow-up calendar
  • proper date of follow-up (window period) adequate imple-
mentation
  • place where patients report for follow-up (health center/
home):
  • Adequacy of facility
  • Opening time
  • Staff
  • CRF being sent regularly to data management centre in   
country:
  • Frequency of submission
  • Completeness, backlogs
  • Data management (data entry progress, due, done,   
entered, etc):
  • no. of forms due
  • no. of forms completed
  • no. of forms entered
  • no of forms still to be entered
  • problems with data entry
  • Regular transmission of electronic data to the central data 
coordination center:
  • expected frequency
  • Actual frequency
  • Security of data (password protection):
  • Sites of storage
  • Frequency of backups
  • Date of last backup
  • Communication with central DCC and WHO:
  • Frequency
  • Date of last communication
  • Inventory and storage and protection of study medicines:
  • Definition of responsible staff
  • Frequency of inventory
  • Date of last inventory
  • Adequacy of facility (security, temperature, stocktaking)
  • Dispensing record for study medicines
  • Collection of used needles, syringes, medicine vials and bot-
tles and proper storage/disposal
  • Fund utilization:
  • expected expenditure
  • Actual expenditure
  • explanation for differences >10%
  • Situation of supplies/reordering of supplies
2.  ReVIeW OF SuBJeCt ReCORDS1
  • Check filled CRFs (10–20% new cases since the last visit)
  • Check all (or at least 50% new cases since the last visit) treat-
ment failure/outcome assessment and serious adverse events 
forms CRFs
3.  OBSeRVAtIOn OF KeY StuDY pROCeDuReS
  • Screening, enrollment and randomization2
  • Administering the consent form
  • management of patients (including preparation of study 
medicine and dispensing of medicines in accordance with 
the study protocol)
  • Outcome assessment
  • Consistency in measurements between various levels (CHW, 
study health worker, outcome assessment nurse and supervi-
sor)
  • Home visits to see some enrolled infants and interview   
mothers/caretakers4
  • Follow-up of patients
  • Completing follow-up information
  • Communication between study staff and potential/enrolled 
patients’ families
  • Data entry, double data entry and cleaning
  • making backups
  • Audit trail
4. StAnDARDIZAtIOn
  • Review presence of training materials and training/ 
retraining records as per standard operating procedures.
  • Standardization records as per standard operating proce-
dures.
  • Interviews with a sample of data collectors to confirm that 
processes being used are according to the standard operating 
procedures.
  • Organize a standardization session for key measurements 
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5.  SIte mOnItORInG RepORt
  • Feedback and action for principal investigator
  • Recommendations and actions for WHO
  • Report prepared and submitted
  • Date and signature
NOTES
1. there are no omissions or discrepancies in the reports of specific 
data elements such as weight, age, clinical signs, correlation of 
clinical signs with assessment and diagnosis, outcome assess-
ment and treatment, randomization code, correlation of rand-
omization code with treatment regimen, correlation of weight 
and treatment doses, adherence to treatment and serious adverse 
events.
2. During a site visit, there may not be any enrollment, randomi-
zation and treatment identification or administration of consent 
form. In that case, home visits are made to see some enrolled 
infants and interview mothers/caretakers.